{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:21:47Z","timestamp":1771294907834,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA052425"],"award-info":[{"award-number":["R01DA052425"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01AA029097"],"award-info":[{"award-number":["R01AA029097"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dadr.2025.100374","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:01:08Z","timestamp":1755878468000},"page":"100374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Relationship between Medicaid coverage design and receipt of medication for alcohol use disorder (MAUD): Probability of receipt increases based on comprehensiveness of plan"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-2200","authenticated-orcid":false,"given":"Miguel Antonio Garcia","family":"Estrada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-1843","authenticated-orcid":false,"given":"Shelby R.","family":"Steuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-1604","authenticated-orcid":false,"given":"Christina M.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen M.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-4079","authenticated-orcid":false,"given":"Olivia M.","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily C.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-6094","authenticated-orcid":false,"given":"Felipe","family":"Lozano-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Westlake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coady","family":"Wing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-7464","authenticated-orcid":false,"given":"Amanda J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2025.100374_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13311-019-00814-4","article-title":"Availability of medications for the treatment of alcohol and opioid use disorder in the USA","volume":"17","author":"Abraham","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.dadr.2025.100374_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.4001","article-title":"Coverage and prior authorization policies for medications for opioid use disorder in medicaid managed care","volume":"3","author":"Abraham","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.dadr.2025.100374_bib3","article-title":"Combined pharmacological and psychosocial interventions for alcohol use disorder","author":"Agabio","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.dadr.2025.100374_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1377\/hlthaff.2023.00288","article-title":"Medicaid managed care prior authorization for buprenorphine tied to state partisanship and health plan profit status, 2018","volume":"43","author":"Andrews","year":"2024","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.dadr.2025.100374_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200014050-00001","article-title":"Does disulfiram help to prevent relapse in alcohol abuse?","volume":"14","author":"Brewer","year":"2000","journal-title":"CNS Drugs"},{"key":"10.1016\/j.dadr.2025.100374_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2024.8325","article-title":"Expanding alcohol use disorder medications in primary care","author":"Busch","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.dadr.2025.100374_bib7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol use disorders","volume":"394","author":"Carvalho","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dadr.2025.100374_bib8","unstructured":"Center for Behavioral Health Statistics and Quality, 2019. 2019 National Survey on Drug Use and Health (NSDUH) Releases [WWW Document]. URL \u3008https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt29394\/NSDUHDetailedTabs2019\/NSDUHDetTabsSect2pe2019.htm#table2-17a\u3009"},{"key":"10.1016\/j.dadr.2025.100374_bib9","series-title":"2023 national survey on drug use and health","author":"Center for Behavioral Health Statistics and Quality","year":"2024"},{"key":"10.1016\/j.dadr.2025.100374_bib10","unstructured":"Centers for Medicare & Medicaid Services,n.d. Identifying beneficiaries with a treated substance use disorder (SUD): Reference codes."},{"key":"10.1016\/j.dadr.2025.100374_bib11","unstructured":"Centers for Medicare and Medicaid Services, 2022. December 2021 and January 2022 Medicaid and CHIP Enrollment Trends Snapshot. Medicaid CHIP Learn. Collab. URL \u3008https:\/\/www.medicaid.gov\/medicaid\/national-medicaid-chip-program-information\/downloads\/dec-2021-jan-2022-medicaid-chip-enrollment-trend-snapshot.pdf\u3009"},{"key":"10.1016\/j.dadr.2025.100374_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1192\/bjp.161.1.84","article-title":"Disulfiram treatment of alcoholism","volume":"161","author":"Chick","year":"1992","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib13","unstructured":"Chronic Conditions Warehouse, 2024. Other Chronic Health, Mental Health, and Potentially Disabling Chronic Conditions Algorithms: MBSF_OTCC_{YYYY} File."},{"key":"10.1016\/j.dadr.2025.100374_bib14","unstructured":"Corallo, B., Garfield, R., 2021. Medicaid Enrollment Churn and Implications for Continuous Coverage Policies [WWW Document]. Medicaid. URL \u3008https:\/\/www.kff.org\/report-section\/medicaid-enrollment-churn-and-implications-for-continuous-coverage-policies-issue-brief\/\u3009 (accessed 10.14.24)."},{"key":"10.1016\/j.dadr.2025.100374_bib15","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7308a1","article-title":"Deaths from excessive alcohol use \u2014 United States, 2016\u20132021","volume":"73","author":"Esser","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.dadr.2025.100374_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1360-0443.2004.00597.x","article-title":"Does disulfiram have a role in alcoholism treatment today?","volume":"99","author":"Fuller","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100374_bib17","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of Long-Acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.dadr.2025.100374_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","article-title":"Prevalence of 12-Month alcohol use, High-Risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from The National epidemiologic survey on alcohol and related conditions","volume":"74","author":"Grant","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US: results from the 2019 national survey on drug use and health","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib20","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1007\/s11606-024-09002-3","article-title":"Medications for alcohol use disorder: rates and predictors of prescription order and fill in outpatient settings","volume":"39","author":"Hodgkin","year":"2024","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.dadr.2025.100374_bib21","article-title":"Prevalence and treatment for alcohol use disorders based on kentucky medicaid 2012\u20132019 datasets","volume":"10","author":"Hu","year":"2022","journal-title":"J. Alcohol. Drug Depend."},{"key":"10.1016\/j.dadr.2025.100374_bib22","unstructured":"Kaiser Family Foundation, 2021. Total Medicaid MCO Enrollment. URL \u3008https:\/\/www.kff.org\/other\/state-indicator\/total-medicaid-mco-enrollment\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D\u3009"},{"key":"10.1016\/j.dadr.2025.100374_bib23","unstructured":"Kaiser Family Foundation, 2022. Total Medicaid MCO Enrollment [WWW Document]. State Health Facts. URL \u3008https:\/\/www.kff.org\/other\/state-indicator\/total-medicaid-mco-enrollment\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D\u3009"},{"key":"10.1016\/j.dadr.2025.100374_bib24","unstructured":"Kaiser Family Foundation, 2023. Health Insurance Coverage of the Total Population [WWW Document]. State Health Facts. URL \u3008https:\/\/www.kff.org\/other\/state-indicator\/total-population\/?dataView=1&currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D\u3009"},{"key":"10.1016\/j.dadr.2025.100374_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.drugalcdep.2018.06.015","article-title":"Study characteristics influence the efficacy of substance abuse treatments: a meta-analysis of medications for alcohol use disorder","volume":"190","author":"Klemperer","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2025.100374_bib26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S2215-0366(19)30213-5","article-title":"Prevention, screening, and treatment for heavy drinking and alcohol use disorder","volume":"6","author":"Knox","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ajp.20230488","article-title":"Overview of alcohol use disorder","volume":"180","author":"Kranzler","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.dadr.2025.100374_bib29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","article-title":"Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, Placebo-Controlled clinical trial","volume":"28","author":"Kranzler","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.dadr.2025.100374_bib30","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1001\/jama.2017.4760","article-title":"More treatments on deck for alcohol use disorder","volume":"317","author":"Lyon","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.dadr.2025.100374_bib31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1037\/ccp0000447","article-title":"A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition","volume":"87","author":"Magill","year":"2019","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.dadr.2025.100374_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100374_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhealeco.2017.04.006","article-title":"Medicaid program choice, inertia and adverse selection","volume":"56","author":"Marton","year":"2017","journal-title":"J. Health Econ."},{"key":"10.1016\/j.dadr.2025.100374_bib34","unstructured":"Medicaid and CHIP Payment and Access Commission, 2019. State plan [WWW Document]. URL \u3008https:\/\/www.macpac.gov\/subtopic\/state-plan\/\u3009"},{"key":"10.1016\/j.dadr.2025.100374_bib35","unstructured":"Medicaid and CHIP Payment and Access Commission, 2023. Managed care\u2019s effect on outcomes [WWW Document]. Manag. Care. URL \u3008https:\/\/www.macpac.gov\/subtopic\/managed-cares-effect-on-outcomes\/\u3009"},{"key":"10.1016\/j.dadr.2025.100374_bib36","unstructured":"Mee-Lee, D., 2013. The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions, 3rd edition. ed. The Change Companies."},{"key":"10.1016\/j.dadr.2025.100374_bib37","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/add.15357","article-title":"Treatment rates for alcohol use disorders: a systematic review and meta-analysis","volume":"116","author":"Mekonen","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100374_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/jcp.0b013e31814ce50d","article-title":"Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment","volume":"27","author":"O\u2019Malley","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.dadr.2025.100374_bib39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study","volume":"49","author":"O\u2019Malley","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1377\/hlthaff.2018.0124","article-title":"Impact of medicaid expansion on coverage and treatment of Low-Income adults with substance use disorders","volume":"37","author":"Olfson","year":"2018","journal-title":"Health Aff."},{"key":"10.1016\/j.dadr.2025.100374_bib41","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib42","unstructured":"Palmer, A., Howell, E., Costich, J., Kenney, G.M., 2012. Evaluation of Statewide Risk-Based Managed Care in Kentucky: A First Year Implementation Report. Urban Institute, Washington, DC."},{"key":"10.1016\/j.dadr.2025.100374_bib43","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1377\/hlthaff.2023.01023","article-title":"Most states allow medicaid managed care plans discretion to restrict substance use disorder treatment benefits","volume":"43","author":"Peterson","year":"2024","journal-title":"Health Aff."},{"key":"10.1016\/j.dadr.2025.100374_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2015.09.006","article-title":"Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review","volume":"61","author":"Priester","year":"2016","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2025.100374_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.dadr.2025.100374_bib46","article-title":"Opioid antagonists for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Libr"},{"key":"10.1016\/j.dadr.2025.100374_bib47","article-title":"Acamprosate for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.dadr.2025.100374_bib48","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1176\/appi.ps.201400160","article-title":"Perceived barriers to treatment for alcohol problems: a latent class analysis","volume":"66","author":"Schuler","year":"2015","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.dadr.2025.100374_bib49","article-title":"Substance use disorder treatment carve outs in medicaid managed care","volume":"161","author":"Silverman","year":"2024","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.dadr.2025.100374_bib50","doi-asserted-by":"crossref","first-page":"s69","DOI":"10.1111\/j.1521-0391.2003.tb00497.x","article-title":"Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a european perspective","volume":"12","author":"Soyka","year":"2003","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.dadr.2025.100374_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/1475-6773.14394","article-title":"Medicaid managed care restrictions on medications for the treatment of opioid use disorder","volume":"60","author":"Stewart","year":"2025","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.dadr.2025.100374_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0695","article-title":"Alcohol use disorder medication coverage and utilization management in medicaid managed care plans","volume":"8","author":"Stewart","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2025.100374_bib53","unstructured":"Substance Abuse and Mental Health Services Administration, 2015. Medication for the treatment of alcohol use disorder: A brief guide. Rockville, MD."},{"key":"10.1016\/j.dadr.2025.100374_bib54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.dadr.2025.100374_bib55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsat.2016.07.010","article-title":"Transitioning from detoxification to substance use disorder treatment: facilitators and barriers","volume":"70","author":"Timko","year":"2016","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2025.100374_bib56","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch. Gen. Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.dadr.2025.100382","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:25:17Z","timestamp":1766179517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724625000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"alternative-id":["S2772724625000575"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100374","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between Medicaid coverage design and receipt of medication for alcohol use disorder (MAUD): Probability of receipt increases based on comprehensiveness of plan","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100374"}}